Objective Belimumab has been proven to be effective for treating refractory lupus nephritis. However, the meaningful renal ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and ...
CAR T cell therapy achieved high remission rates with manageable safety in relapsed diffuse large B cell lymphoma. - EMJ ...
SYDNEY & DUARTE, Calif.--(BUSINESS WIRE)--Imugene Ltd (ASX:IMU), an immuno-oncology company and City of Hope, a world-renowned independent cancer research and treatment center near Los Angeles, today ...
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial This phase II trial enrolled 225 evaluable ...
Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T-cell-targeted lipid nanoparticle carrying CD19 CAR mRNA (HN2301) generated ...
Los Angeles, USA, May 10, 2021 (GLOBE NEWSWIRE) -- Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela ...
New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple ...
A pretreatment axial PET-CT image (Panel A) shows an intracranial abnormality in the right middle cranial fossa and extensive abnormality in subcutaneous tissues in the right posterior auricular ...
B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat rheumatoid arthritis and other autoimmune diseases. CD20-targeted immunotherapy depletes mature B cells through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results